EXEL: Exelixis, Inc. Stock

by  •  • Comments Off on EXEL: Exelixis, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 9,821.04
Enterprise Value ($M) 9,603.67
Book Value ($M) 2,244.20
Book Value / Share 8.02
Price / Book 4.38
NCAV ($M) 764.09
NCAV / Share 2.73
Price / NCAV 12.85

Profitability (mra)
Return on Invested Capital (ROIC) 0.21
Return on Assets (ROA) 0.18
Return on Equity (ROE) 0.23

Liquidity (mrq)
Quick Ratio 3.58
Current Ratio 3.63

Balance Sheet (mrq) ($M)
Current Assets 1,467.58
Assets 2,947.69
Liabilities 703.49
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2,168.70
Operating Income 689.95
Net Income 521.27
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 699.97
Cash from Investing -116.78
Cash from Financing -628.81

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-08 13D/A Farallon Capital Partners, L.P. 9.20 3.52
2024-02-13 13G Renaissance Technologies Llc 5.16 4.38
2024-02-13 13G/A Vanguard Group Inc 10.18 -1.91
2024-01-24 13G/A BlackRock, Inc. 11.60 4.30

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 620,123 3,013,321 20.58
2025-02-20 279,445 1,379,909 20.25
2025-02-19 355,938 2,029,493 17.54
2025-02-18 319,654 2,113,213 15.13

(click for more detail)

Similar Companies
ENTA – Enanta Pharmaceuticals, Inc. ERAS – Erasca, Inc.
EWTX – Edgewise Therapeutics, Inc. FDMT – 4D Molecular Therapeutics, Inc.
FGEN – FibroGen, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Exelixis